Mayo Clinic launches 50-gene cancer panel test

Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor. CANCP, an abbreviation for Solid Tumor Targeted Cancer Gene Panel by Next-Generation Sequencing, scans specific regions in 50 genes known to affect tumor growth and response to chemotherapy. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.

"Every patient's cancer is different, and oncology is moving away from treating cancer based on its location in the body in favor of selecting the best medication for the individual patient based on molecular changes in the tumor," says Axel Grothey, M.D., a Mayo Clinic oncologist who orders CANCP on selected tumors. "This test helps providers identify such molecular changes without infusing irrelevant details from genes that we know will not affect our choice of medications."

The test is a hotspot panel, which means it scans specific regions of individual genes—rather than the entire gene—in search of tumor mutations that influence response to . It is designed for testing of solid tumors and focuses on clinically actionable alterations.

"We worked closely with oncologists, pathologists and molecular geneticists to develop and implement a assay that will have actionable results for providers," says Benjamin Kipp, Ph.D., a Mayo Clinic molecular geneticist and CANCP's lead designer. "This test focuses on results that oncologists can use to help find the right drug the first time."

Testing is conducted in the CLIA-certified Next-Generation Sequencing Lab of the Mayo Clinic Department of Laboratory Medicine and Pathology (DLMP). This is the second next-generation sequencing panel test offered by DLMP and Mayo Medical Laboratories. The other is a 17-gene screening for hereditary colorectal cancers. Both were developed in collaboration with the Mayo Clinic Center for Individualized Medicine.

add to favorites email to friend print save as pdf

Related Stories

Mayo Clinic launches whole genome breast cancer study

Apr 09, 2012

The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors. Mayo Clinic researchers ...

Physicians target the genes of lung, colon cancers

Apr 16, 2014

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

Recommended for you

Video: Is that double mastectomy really necessary?

9 minutes ago

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

13 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

User comments